ATHXQ.US Athersys, Inc.
- Market cap
- USD 617.00
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 4 quarters up to Sep 2023.
Is ATHXQ.US undervalued?
Graham numberThe Graham number of Athersys, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Athersys, Inc. fundamental analysis
No fundamental analysis for Athersys, Inc. yet.
Athersys, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Athersys, Inc.
Athersys, Inc., a clinical-stage biotechnology company, develops therapies in the regenerative medicine area. Its stem cell product candidate is the MultiStem cell therapy, an allogeneic stem cell product for the treatment of indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as other critical care conditions. The company was founded in 1995 and is headquartered in Cleveland, Ohio. On September 24, 2024, the voluntary petition…
Full company profileAthersys, Inc. financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 4 quarters up to Sep 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Athersys, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 5.52M | 1.43M | 5.51M | 5.33M | 80.0K |
| Operating Income | -45.5M | -78.3M | -87.1M | -77.0M | -41.8M |
| EBITDA | - | - | -85.6M | -75.6M | - |
| Net Income | -44.6M | -78.8M | -87.0M | -72.5M | -37.5M |
| EPS | -6.98 | -9.75 | -8.95 | -4.03 | -1.40 |
| Balance Sheet | |||||
| Total Assets | 41.7M | 59.7M | 60.2M | 27.7M | 7.43M |
| Total Liabilities | 18.4M | 28.4M | 43.8M | 51.6M | 43.8M |
| Shareholders' Equity | 23.3M | 31.4M | 16.4M | -23.9M | -36.4M |
| Cash & Short-term Investments | 35.0M | 51.5M | 37.4M | 9.04M | 1.02M |
| Cash Flow | |||||
| Operating Cash Flow | -35.3M | -61.8M | -76.2M | -59.0M | -26.4M |
| Capital Expenditure | 579K | 1.16M | 1.36M | 397K | 0.00 |
| Free Cash Flow | -35.9M | -63.0M | -77.5M | -59.3M | -24.7M |
| Ratios | |||||
| ROE | -191.6% | -251.1% | -531.2% | - | - |
| ROA | -107.0% | -131.9% | -144.5% | -261.6% | -504.9% |
| Net Profit Margin | -808.1% | -5,500.3% | -1,577.0% | -1,362.1% | -46,883.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Athersys, Inc. dividends
Athersys, Inc. has not paid dividends in the last 4 fiscal years.
Last stock split: 1:25 on Aug 29, 2022.
Who owns Athersys, Inc.
- Insiders 0.00%
- Institutions 0.00%
- Public & others 100.00%
- Shares outstanding 61.7M
- Free float 61.7M
Athersys, Inc. company profile
- Company name
- Athersys, Inc.
- Ticker
- ATHXQ.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 24
- Fiscal year end
- September
- Address
- 3201 Carnegie Avenue, Cleveland, OH, United States, 44115-2634
- Phone
- 216 431 9900
- Website
- athersys.com
About Athersys, Inc.
Athersys, Inc., a clinical-stage biotechnology company, develops therapies in the regenerative medicine area. Its stem cell product candidate is the MultiStem cell therapy, an allogeneic stem cell product for the treatment of indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as other critical care conditions. The company was founded in 1995 and is headquartered in Cleveland, Ohio. On September 24, 2024, the voluntary petition of Athersys, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy along with its affiliates on January 5, 2024.
Athersys, Inc. management
8- Ms. Z. Kasey RosadoInterim CFO & Director · born 1974
- Dr. Senthil Ranganathan Ph.D.Vice President of Technical Operations
- Mr. David Russ M.B.A.Vice President of Supply Chain, Finance & Administration
- Dr. Manal Morsy M.B.A., M.D., PH.D.Executive VP & Head of Global Regulatory Affairs
- Dr. Robert Mays Ph.D.Executive VP, Head of Regenerative Medicine & Neuroscience Programs
- Mr. Rakesh Ramachandran MSHead of Information Technology & Communications and VP
- Dr. Sarah Busch Ph.D.VP of Regenerative Medicine & Head of Business Development
- Ms. Ellen GurleyManager of Corporate Communications and Investor Relations